Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium
Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort
Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…Abstract Number: 132 • 2020 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
Background/Purpose: Pediatric rheumatology has been an evolving subspecialty over the last few decades with a continued increase in the both the number and severity of…Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…Abstract Number: 876 • 2019 ACR/ARP Annual Meeting
“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Background/Purpose: Although patient-reported outcome measures (PROMs) are extensively used in clinical practice and research, it is unclear whether the most commonly used instruments adequately cover…Abstract Number: 1153 • 2019 ACR/ARP Annual Meeting
Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population
Background/Purpose: The potential for reactivation of tuberculosis (TB) in patients treated with anti-TNF or other immunosuppressive agents has been well described. Interferon-gamma release assays (IGRA)…Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…Abstract Number: 2192 • 2019 ACR/ARP Annual Meeting
Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
Background/Purpose: Based on data from the Osteoarthritis Initiative (OAI), MRI-based analyses of bone shape changes in the knee predict symptomatic and radiographic progression of knee…Abstract Number: 2242 • 2019 ACR/ARP Annual Meeting
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Background/Purpose: The FDA uses near or total clearance in cutaneous disease in inflammatory skin conditions as an endpoint in clinical trials. However, patients may experience…Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
- 1
- 2
- 3
- …
- 9
- Next Page »